Alex L. Roederer

Dec 8, 2024 | cell.com | Alex L. Roederer |Yi Cao |Kerri St. Denis |Maegan L. Sheehan |Evan C. Lam |David Gregory | +6 more

KeywordsCOVID-19SARS-CoV-2variantsvaccinationneutralizing antibodiesinfectivitybreadthIntroductionSince it was described in late 2019, SARS-CoV-2 has undergone continuous evolution.

Mar 7, 2024 | medrxiv.org | Alex L. Roederer |Yi Cao |Kerri St. Denis |Maegan L. Sheehan

A.B.B. is a founder of Cure Systems LLC. A.B.B. was supported by NIAID R01s AI174875, AI174276, the NIDA Avenir New Innovator Award DP2DA040254 a Massachusetts Consortium on Pathogenesis Readiness (MassCPR) grant and CDC subcontract 200-2016-91773-T.O.2.I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.